This database includes MPT products that are currently available, as well as MPT products in active development. The database outlines detailed product information and can be searched to display products by desired criteria as selected from the drop-down boxes or by entering a keyword in the search box. Click on the product name to access detailed information on each product. Please note there are other MPT candidates not listed that may move forward pending funding. Click here to learn more about the inclusion criteria and information update methodology.
Know of an MPT product not included in this database or have updated information for listed products? Let us know here!
Click on the table for MPT products in the development pipeline by indication combination.
Dual Prevention Pill (DPP) Regimen
MPT in Development
Clinical - Phase 4 (Post-marketing) Trial (C4)
Delivery Route & Method:
Children’s Investment Fund Foundation (CIFF)
National Institutes of Health (NIH)
U.S. Agency for International Development (USAID)
NIH: NIMH R34
Combined Oral Contraceptive (COC)
Ethinyl Estradiol (EE)
Tenofovir Disoproxil Fumarate (TDF)
Description: A 28-day contraceptive pill regimen that also provides protection against HIV. 21 pills will contain Truvada and EE/LNG; 7 pills will contain Truvada only. API compatibility (TDF/FTC with EE/LNG and excipients) confirmed. Acceptability studies with over-encapsulated Truvada and COC planned in Zimbabwe and South Africa to start in Q1 2021. Prototype development on hold while seeking additional funding.
This project is made possible by the generous support of the American people through the United States Agency for International Development (USAID) under the terms of Cooperative Agreement #AID-OAA-A-16-00045. The contents are the responsibility of the IMPT, CAMI Health, PHI, and its partners and do not necessarily reflect the views of USAID or the U.S. Government.